A cross-disease resource of living human microglia identifies disease-enriched subsets and tool compounds recapitulating microglial states

• Published in: Nature neuroscience
• Main Authors: Tuddenham, John F., Taga, Mariko, Haage, Verena, Marshe, Victoria S., Roostaei, Tina, White, Charles, Lee, Annie J., Fujita, Masashi, Khairallah, Anthony, Zhang, Ya, Green, Gilad, Hyman, Bradley, Frosch, Matthew, Hopp, Sarah, Beach, Thomas G., Serrano, Geidy E., Corboy, John, Habib, Naomi, Klein, Hans-Ulrich, Soni, Rajesh Kumar, Teich, Andrew F., Hickman, Richard A., Alcalay, Roy N., Shneider, Neil, Schneider, Julie, Sims, Peter A., Bennett, David A., Olah, Marta, Menon, Vilas, De Jager, Philip L.
• Format: Journal Article
• Language: English
• Published: 15.10.2024
• ISSN: 1097-6256; 1546-1726; 1546-1726
• DOI: 10.1038/s41593-024-01764-7

Human microglia play a pivotal role in neurological diseases, but we still have an incomplete understanding of microglial heterogeneity, which limits the development of targeted therapies directly modulating their state or function. Here, we use single-cell RNA sequencing to profile 215,680 live human microglia from 74 donors across diverse neurological diseases and CNS regions. We observe a central divide between oxidative and heterocyclic metabolism and identify microglial subsets associated with antigen presentation, motility and proliferation. Specific subsets are enriched in susceptibility genes for neurodegenerative diseases or the disease-associated microglial signature. We validate subtypes in situ with an RNAscope-immunofluorescence pipeline and high-dimensional MERFISH. We also leverage our dataset as a classification resource, finding that induced pluripotent stem cell model systems capture substantial in vivo heterogeneity. Finally, we identify and validate compounds that recapitulate certain subtypes in vitro, including camptothecin, which downregulates the signature of disease-enriched subtypes and upregulates a signature previously associated with Alzheimer's disease.Human microglia play a pivotal role in neurological diseases, but we still have an incomplete understanding of microglial heterogeneity, which limits the development of targeted therapies directly modulating their state or function. Here, we use single-cell RNA sequencing to profile 215,680 live human microglia from 74 donors across diverse neurological diseases and CNS regions. We observe a central divide between oxidative and heterocyclic metabolism and identify microglial subsets associated with antigen presentation, motility and proliferation. Specific subsets are enriched in susceptibility genes for neurodegenerative diseases or the disease-associated microglial signature. We validate subtypes in situ with an RNAscope-immunofluorescence pipeline and high-dimensional MERFISH. We also leverage our dataset as a classification resource, finding that induced pluripotent stem cell model systems capture substantial in vivo heterogeneity. Finally, we identify and validate compounds that recapitulate certain subtypes in vitro, including camptothecin, which downregulates the signature of disease-enriched subtypes and upregulates a signature previously associated with Alzheimer's disease.